Asterias Stock Today

Asterias Biotherapeutics cannot be verified against its exchange. It appears that Asterias Biotherapeutics is not available for investing at the moment. Please verify the symbol is currently traded on NYSEMKT Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Asterias Biotherapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Asterias Biotherapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Asterias Biotherapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Asterias Biotherapeutics is not currently marked as verified by its exchange. Report It!
Older SymbolASTY
President CEO, DirectorMichael Mulroy
Fama & French Classification
Average Analyst Recommendation
Analysts covering Asterias Biotherapeutics report their recommendations after researching Asterias Biotherapeutics' financial statements, talking to executives and customers, or listening in on Asterias Biotherapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Asterias Biotherapeutics. The Asterias consensus assessment is calculated by taking the average forecast from all of the analysts covering Asterias Biotherapeutics.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Asterias Biotherapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Asterias Biotherapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares48.8 M45.2 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted48.8 M45.2 M
Significantly Up
Increasing
Slightly volatile
Total Assets41.2 M38.8 M
Notably Up
Increasing
Slightly volatile
Total Liabilities10.8 M8.6 M
Significantly Up
Increasing
Stable
Current Assets21.8 M20.4 M
Notably Up
Increasing
Slightly volatile
Current Liabilities4.2 MM
Fairly Up
Decreasing
Very volatile
Total Debt29.5 K29.7 K
Slightly Down
Decreasing
Slightly volatile
Gross Margin85.3286.33
Fairly Down
Decreasing
Stable
Asset Turnover0.06520.0699
Significantly Down
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Asterias Biotherapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedUndervalued
Financial Strength
Asterias Biotherapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Asterias Biotherapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Asterias Biotherapeutics' financial leverage. It provides some insight into what part of Asterias Biotherapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Asterias Biotherapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Asterias Biotherapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Asterias Biotherapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 16 K in debt with debt to equity (D/E) ratio of 0.16, which may show that the company is not taking advantage of profits from borrowing. Asterias Biotherapeutics has a current ratio of 6.37, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Asterias Biotherapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Asterias Biotherapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Asterias Biotherapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Asterias to invest in growth at high rates of return. When we think about Asterias Biotherapeutics' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(30.32 Million)
Asterias Biotherapeutics (AST) is traded on NYSEMKT Exchange in USA. It is located in 6300 Dumbarton Circle, Fremont, CA 94555, United States and employs 31 people. Asterias Biotherapeutics was previously known as ASTERIAS BIOTHERAPEUTICS INC and was traded on NYSEMKT Exchange under the symbol ASTY. Asterias Biotherapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with total capitalization of 52.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Asterias Biotherapeutics's market, we take the total number of its shares issued and multiply it by Asterias Biotherapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Asterias Biotherapeutics runs under null sector within null industry. The entity has 55.66 M outstanding shares of which 409.74 K shares are presently shorted by investors with about 2.31 days to cover. Asterias Biotherapeutics has about 12.59 M in cash with (15.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of -0.6103.
Check Asterias Biotherapeutics Probability Of Bankruptcy

Asterias Stock Against Markets

Picking the right benchmark for Asterias Biotherapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Asterias Biotherapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Asterias Biotherapeutics is critical whether you are bullish or bearish towards Asterias Biotherapeutics at a given time.
Asterias Biotherapeutics cannot be verified against its exchange. It appears that Asterias Biotherapeutics is not available for investing at the moment. Please verify the symbol is currently traded on NYSEMKT Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Try Other Stock Suggestions

Asterias Biotherapeutics Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Asterias Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Asterias Biotherapeutics could also be used in its relative valuation, which is a method of valuing Asterias Biotherapeutics by comparing valuation metrics with similar companies.
Apple IncMicrosoft CorpUnitedhealth GroupTaiwan Semiconductor ADRNvidia CorpWalmartAmn Healthcare ServicesTwist Bioscience CorpFreedom Holding CorpKEURIG DR PEPPERGx Nasdaq-100 CoveredFranklin Mutual EuropeanGARDNER DENVER INCUSA Value FactorBetapro Canadian Gold
 Risk & Return  Correlation

Asterias Biotherapeutics Corporate Directors

Asterias Biotherapeutics corporate directors refer to members of an Asterias Biotherapeutics board of directors. The board of directors generally takes responsibility for the Asterias Biotherapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Asterias Biotherapeutics' board members must vote for the resolution. The Asterias Biotherapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Mykola Kovalski - Marketing and Communications DirectorProfile
Michael West - VP of Technology Integration and DirectorProfile
Marcus Campen - Independent Executive Director, Chief Corporate OfficerProfile
Viktor Gladkyi - CFO, Executive Director, Member of the Management TeamProfile

Invested in Asterias Biotherapeutics?

You need to understand the risk of investing before taking a position in Asterias Biotherapeutics. The danger of trading Asterias Biotherapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Asterias Biotherapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Asterias Biotherapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Asterias Biotherapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Trending Equities. Note that the Asterias Biotherapeutics information on this page should be used as a complementary analysis to other Asterias Biotherapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Tools for Asterias Stock

When running Asterias Biotherapeutics price analysis, check to measure Asterias Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Asterias Biotherapeutics is operating at the current time. Most of Asterias Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Asterias Biotherapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Asterias Biotherapeutics' price. Additionally, you may evaluate how the addition of Asterias Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go